173 related articles for article (PubMed ID: 37445688)
1. Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.
Culletta G; Tutone M; Ettari R; Perricone U; Di Chio C; Almerico AM; Zappalà M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445688
[TBL] [Abstract][Full Text] [Related]
2. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.
Ettari R; Cerchia C; Maiorana S; Guccione M; Novellino E; Bitto A; Grasso S; Lavecchia A; Zappalà M
ChemMedChem; 2019 Apr; 14(8):842-852. PubMed ID: 30829448
[TBL] [Abstract][Full Text] [Related]
3. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
[TBL] [Abstract][Full Text] [Related]
4. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
6. Development of isoquinolinone derivatives as immunoproteasome inhibitors.
Ettari R; Iraci N; Di Chio C; Previti S; Danzè M; Zappalà M
Bioorg Med Chem Lett; 2022 Jan; 55():128478. PubMed ID: 34838650
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
8. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i.
Allardyce DJ; Bell CM; Loizidou EZ
Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944
[TBL] [Abstract][Full Text] [Related]
9. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening.
Scarpino A; Bajusz D; Proj M; Gobec M; Sosič I; Gobec S; Ferenczy GG; Keserű GM
Molecules; 2019 Jul; 24(14):. PubMed ID: 31315311
[TBL] [Abstract][Full Text] [Related]
11. Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods.
Culletta G; Zappalà M; Ettari R; Almerico AM; Tutone M
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279386
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
13. Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells.
Ettari R; Pallio G; Pizzino G; Irrera N; Zappalà M; Maiorana S; Di Chio C; Altavilla D; Squadrito F; Bitto A
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1307-1313. PubMed ID: 31307247
[TBL] [Abstract][Full Text] [Related]
14. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Maurits E; Degeling CG; Kisselev AF; Florea BI; Overkleeft HS
Chembiochem; 2020 Nov; 21(22):3220-3224. PubMed ID: 32598532
[TBL] [Abstract][Full Text] [Related]
16. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
17. Discovery of selective fragment-sized immunoproteasome inhibitors.
Kollár L; Gobec M; Szilágyi B; Proj M; Knez D; Ábrányi-Balogh P; Petri L; Imre T; Bajusz D; Ferenczy GG; Gobec S; Keserű GM; Sosič I
Eur J Med Chem; 2021 Jul; 219():113455. PubMed ID: 33894528
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.
Zhan W; Singh PK; Ban Y; Qing X; Ah Kioon MD; Fan H; Zhao Q; Wang R; Sukenick G; Salmon J; Warren JD; Ma X; Barrat FJ; Nathan CF; Lin G
J Med Chem; 2020 Nov; 63(21):13103-13123. PubMed ID: 33095579
[TBL] [Abstract][Full Text] [Related]
19. Immunoproteasome subunit β5i regulates diet-induced atherosclerosis through altering MERTK-mediated efferocytosis in Apoe knockout mice.
Liao J; Xie Y; Lin Q; Yang X; An X; Xia Y; Du J; Wang F; Li HH
J Pathol; 2020 Mar; 250(3):275-287. PubMed ID: 31758542
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i).
Scheffler S; Kuckelkorn U; Egerer K; Dörner T; Reiter K; Soza A; Burmester GR; Feist E
Rheumatology (Oxford); 2008 May; 47(5):622-6. PubMed ID: 18375405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]